Clinical trial
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
NCT00132301 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00132301 |
|---|---|
| Title | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma |
| Official title | CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment |
| Acronym | CAP |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Prednisone |
| Enrollment | 298 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2015 |
| Completion | Sep 1, 2016 |
| First posted | Aug 19, 2005 |
| Last update posted | Jun 25, 2018 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: